(RTTNews) – Novo Nordisk A/S (NVO) reported that a net distinction for a initial half of 2017 increasing 4 percent from final year to 20.1 billion Danish kroner. Earnings per share increasing 6 percent to 8.07 kroner.
Sales for a half year increasing 4 percent from final year to 57.1 billion kroner. Sales increasing 3 percent in internal currencies.
Sales of Victoza increasing 21 percent and sales of Tresiba grew 155 percent. Sales in a North America operations increasing 5 percent, while International Operations sales rose 4 percent.
Further, a company’s Board of Directors has authorized an halt division for 2017 of 3.00 kroner per share of 0.20 krone that will be paid in Aug 2017.
Looking forward to mercantile 2017, Novo Nordisk lifted a low finish of a opinion for sales expansion totalled in internal currencies. The association now expects sales expansion in a operation of 1 percent to 3 percent, compared with a prior operation of 0 percent to 3 percent.
The association projects a disastrous banking impact of 3 commission points, reflecting a new and poignant debasement of a U.S. dollar and many other pivotal invoicing currencies contra a Euro and a Danish krone.
Further, Novo Nordisk now expects mercantile 2017 handling distinction expansion totalled in internal currencies to be in a operation of 1 percent to 5 percent, compared with a prior operation of -1 percent to 3 percent.